---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-012903"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2023-08-02T23:59:59+00:00"
generated_at: "2026-06-12T13:02:51.462033+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Coherus Q2 net revenue $58.7M (+81% QoQ); CIMERLI sales quadruple to $26.7M

## Summary
- Net revenue $58.7M, up 81% from prior quarter; UDENYCA $31.7M, CIMERLI $26.7M.
- Net loss $42.9M ($0.49 diluted EPS); non-GAAP net loss $32.8M ($0.38).
- Launched UDENYCA autoinjector in May, YUSIMRY (Humira biosimilar) in July.
- Planned merger with Surface Oncology expected to close after Sep 7 shareholder meeting.
- FDA inspections for toripalimab ongoing; potential approval and launch H2 2023.

## SEC filing metadata
- accession: 0001558370-23-012903
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2023-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000155837023012903/0001558370-23-012903-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000155837023012903/chrs-20230802x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-012903
- JSON: https://secwatch.observer/filing/0001558370-23-012903.json
- Plain text: https://secwatch.observer/filing/0001558370-23-012903.txt

## Key facts
- Earnings Releases
  Coherus Oncology, Inc. reported the second quarter ended June 30, 2023 results: revenue $58.7 million.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $58.7 million
  - Result: reported results
  source text: Net revenue was $58.7 million during the three months ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1512762/000155837023012903/0001558370-23-012903-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.